Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Procurement

We partner, connect and align to shape supplier solutions that help Hovione reach its growth and objectives.

Page
Read more

Areas of Expertise

Hovione analytical chemists master several areas of knowledge

Page
Read more

The Hovione Experience - New Jersey

Welcome to New jersey! From the boardwalk to the shore, bask in The Hovione Experience and let every moment in this bustling state bring you excitement and unforgettable memories.

Page
Read more